
Rapid Micro Biosystems, Inc. (RPID) entered into a merger agreement on November 16, 2026, to be acquired by Merck KGaA in a deal valued at $39 million.
Merck has agreed to acquire all outstanding shares of Rapid Micro Biosystems for $0.75 per share in an all-cash transaction, representing a premium of 15.38% over the stock’s last close.
Rapid Micro Biosystems is a life sciences technology company that develops automated microbial quality control testing systems for pharmaceutical and biopharmaceutical manufacturers. Its flagship Growth Direct platform automates traditional manual testing processes used to detect microbial contamination in products such as biologics, vaccines, and sterile injectables.
Merck KGaA, Darmstadt, Germany, is a global science and technology company operating across three business segments: Life Science, Healthcare, and Electronics. Its life science business provides products, technologies, and services used in pharmaceutical and biopharmaceutical research, drug development, and manufacturing, including laboratory equipment, reagents, and process solutions.
The deal is expected to close in December 2026.
Rapid Micro Biosystems will become part of the life science business of Merck.
Rapid Micro Biosystems has hired Perella Weinberg Partners as its financial advisor and Goodwin Procter as its legal advisor.
Merck is acquiring Rapid Micro Biosystems at a multiple of 0.85 times its sales.
For an in-depth look at the metrics and specifics of this merger and acquisition transaction, please visit the following link:
Deal Metrics for the acquisition of Rapid Micro Biosystems, Inc. (RPID) by Merck KGaA
The Deal Metrics page for each merger or acquisition includes:
Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article